The results for unmanipulated samples and for samples at pH 6.5, 7.3, and 8.0 are summarized in Fig. 1 . Intermediate results were seen at pH 7.0 and 7.6 (not shown). Immediately after the pH manipulation, the ␤-crosslaps increased 0.2-6.6% (P Ͼ0.05). After 2 days, all samples exhibited a significant decrease of the ␤-crosslaps concentrations. In the control samples, ␤-crosslaps decreased by 12% at 37°C and by 5% at room temperature on the second day of storage. After 5 days at room temperature, the decreases in the ␤-crosslaps concentrations in the samples were even more pronounced. The ␤-crosslaps concentrations in the samples stored in the refrigerator remained unchanged.
The results for unmanipulated samples and for samples at pH 6.5, 7.3, and 8.0 are summarized in Fig. 1 . Intermediate results were seen at pH 7.0 and 7.6 (not shown). Immediately after the pH manipulation, the ␤-crosslaps increased 0.2-6.6% (P Ͼ0.05). After 2 days, all samples exhibited a significant decrease of the ␤-crosslaps concentrations. In the control samples, ␤-crosslaps decreased by 12% at 37°C and by 5% at room temperature on the second day of storage. After 5 days at room temperature, the decreases in the ␤-crosslaps concentrations in the samples were even more pronounced. The ␤-crosslaps concentrations in the samples stored in the refrigerator remained unchanged.
In the pH-manipulated aliquots, we observed a positive correlation between the pH and the ␤-crosslaps concentration (Fig. 1) . The lower the serum pH, the lower was the measured concentration of ␤-crosslaps. This pH-dependent decrease in the ␤-crosslaps concentration occurred more rapidly at higher storage temperatures. In the 37°C samples, the decreases at pH 6.5 and 8.0 were 57% and 13%, respectively. The changes in the room temperature samples were similar, but less pronounced, after 2 days. After 5 days at room temperature, the decreases at pH 6.5 and 8.0 were 64% and 7%, respectively. At 4°C, the decreases in ␤-crosslaps were 6 -36% after 5 days and 8 -54% after 10 days. The pH-induced effects were in addition to the changes caused by the various storage procedures.
The explanation for the observed decreases in ␤-crosslaps is not clear. It may, in part, reflect a pH-dependent change of conformation in the octapeptide, from the ␤-form into the isomeric ␣-form, which is not detected by the antibodies of the test. Furthermore, it is not clear whether a switch from the d-to the l-enantiomeric form is of any importance in this assay. Another explanation could be a degradation of the octapeptide or the detecting antibody by proteolytic enzymes in serum with different pH and temperature optima. We conclude that inappropriate preanalytical treatment can significantly complicate clinical interpretation and that standardized preanalytical treatment is necessary. At a serum pH Ͼ8.0, the ␤-crosslaps concentration remains relatively stable for some days if stored in a refrigerator. We recommend centrifugation of the blood samples immediately after their arrival in the laboratory and storage at 4°C (refrigerator) for no more than 5 days. The prothrombin time (PT) is commonly measured by either the "Quick method", which is based on the technique described by Quick and co-workers in 1935 (1, 2 ) , or by the Owren method (3 ) (combined thromboplastin reagent). The latter is the predominant approach used in the Nordic countries, Benelux, and Japan. These two methods are rarely mentioned or noted in the scientific literature (4, 5 ) , and more attention is paid to the thromboplastin in the reagent and to its origin (6, 7 ) .
Agreement of Owren and Quick Prothrombin Times: Effects of Citrate and Calcium Concentrations and In
The Owren method is sensitive to coagulation factors II, VII, and X. Fibrinogen (factor I) and factor V are in the reagent. The Quick method is affected by deficiencies of fibrinogen and factors II, V, VII, and X. Both methods are suitable for the control of anticoagulant treatment. The most important technical difference between the two is the sample volume in the reaction mixture: 5% in the Owren method, and 33% in the Quick method. This has the effect of making the coagulation reaction in the Quick method more sensitive to many preanalytical variables, e.g., citrate concentration in the sample (8, 9 ) . The small sample volume in the reaction mixture with the Owren method makes it possible to use even EDTA plasma (10 ). The International Normalized Ratio (INR) is recommended to harmonize PT results for oral anticoagulant therapy (11 ) . The recommendation conforms with those made by WHO using reference thromboplastins (12 ) . Regardless of the reagent, instrument, or method used, the results should be the same when the INR system is used.
Because these two major PT methods have not previously been compared, the aim of this study was to compare the PT results obtained with two Owren reagents as INR units in samples containing 0.129 mol/L (3.8%) citrate solution and to compare the PT results and clinical significance with the same calibration between one Owren reagent and one Quick reagent as INR units in samples containing 0.129 mol/L (3.8%) and 0.109 mol/L (3.2%) citrate solution. Because calcium (factor IV) is in a key position in coagulation reactions as a cofactor in several steps, we sought to ascertain the ionized calcium (Ca 2ϩ ) concentration in the reaction mixtures in both methods and to study the effect of sample citrate concentration on the Ca 2ϩ concentration in the reaction mixtures by both methods.
All procedures were approved by our institution's responsible committee in accordance with the Helsinki Declaration of 1975. We studied patient samples chosen without conscious bias from among hospital and health center patients; 145 patients were sampled with a citrate coagulation tube (Vacutainer cat. no. 367702, 9NC; Becton Dickinson) containing 0.35 mL of 0.129 mol/L (3.8%) citrate solution (blood volume, 3.15 mL), and 157 patients were sampled with a citrate coagulation tube (Vacuette cat. no. 454327, 9NC; Greiner Labortechnik GmbH) containing 0.35 mL of 0.109 mol/L (3.2%) citrate solution (blood volume, 3.15 mL). The sample needle (Precision Glide, cat. no. 360213; Becton Dickinson) was 0.8 ϫ 38 mm. Sample tubes were centrifuged at 1560g for 10 min at 20°C to separate the plasma.
PT was measured in samples collected in both kinds of sample tubes and reported in INR units. Measurement commenced within 2 h of blood collection. In 30 of the same patients, Ca 2ϩ concentrations were measured in the reaction mixtures for both sample types (0.129 and 0.109 mol/L citrate) and for both methods.
The ACL 1000 and ACL 7000 [Instrumentation Laboratory (IL)] are automatic microcentrifugal analyzers. We measured PT on the ACL 1000 analyzer using Nycotest PT coagulation reagent [cat. no. 1055510; International Sensitivity Index (ISI), 1.006; rabbit brain thromboplastin] and citrate-barbiturate buffer as diluent (cat. no. 1002834; both from Nycomed Pharma), with a 10-L of sample, 50 L of diluent, 140 L of reagent, and IL Test Reference (cat. no. 97569-00).
We measured PT on the ACL 7000 analyzer using Owren's PT coagulation reagent (cat. no. GHI 131-10; ISI; 1.22; rabbit brain thromboplastin), 25 mmol/L CaCl 2 (cat. no. GHI 155) as diluent, Owren buffer [cat. no. GHI 150; all from the Global Hemostasis Institute (GHI)], with a 10-L sample, 50 L of diluent, and 140 L of reagent. We also measured PT on the ACL 7000 analyzer using PT- Within the same run (n ϭ 6), the CVs were as follows: for Nycotest PT, CV ϭ 0.5% (mean, 21.1 s) and 0.4% (mean, 38.8 s); for Owren's PT, CV ϭ 0.4% (mean, 21.2 s) and 0.9% (mean, 35.3 s); for PT-Fibrinogen Recombinant, CV ϭ 0.8% (mean, 12.0 s) and 1.0% (mean, 23.3 s).
The day-to-day CVs were as follows: for Nycotest PT, CV ϭ 1.5% (mean, 20.0 s; n ϭ 14); for Owren's PT, CV ϭ 1.7% (mean, 20.3 s; n ϭ 14); for PT-Fibrinogen Recombinant, CV ϭ 2.0% (mean, 11.7 s; n ϭ 10).
Ionized calcium was measured with an IL 1640 blood gas analyzer, using IL Test contrIL PLUS (cat. no. 98321-30, lot. no. N0208083). The CV was 0.62% at a mean calcium concentration of 1.47 mmol/L (n ϭ 9), 0.71% at 1.09 mmol/L (n ϭ 10), and 1.4% at 0.62 mmol/L (n ϭ 6).
For Ca 2ϩ , we used IL Test Cal 1 (cat. no. 98318-00), Test Cal 2 (cat. no. 98342-00), and Test BGE Flush (cat. no. 98320-00). For Ca 2ϩ measurements, a reaction mixture was prepared with volumes two times those for the ACL (for Owren's PT, 20 L ϩ 100 L ϩ 280 L; for Quick PT, 100 L ϩ 200 L); after coagulation the solution was centrifuged at 12 700g for 10 min, and Ca 2ϩ was measured in the supernatant by an IL 1640. The regression equations for calculating the patient data were as follows: Owren ISI ϫ 1.14 for 0.109 mol/L citrate (Fig. 1B) .
These regression models were applied to convert the results obtained by the Quick and Owren methods to ISI, making its routine use easy.
The regression equations for PT estimation from citrate plasma (0.129 mol/L) were as follows for results obtained as INR: for two Owren reagents, Nycotest PT (x) vs Owren's PT (y), y ϭ 1.08x Ϫ 0.15 (R 2 ϭ 0.99); for the Clinical Chemistry 47, No. 5, 2001 Owren (x; Nycotest PT) and Quick (y) methods, y ϭ 0.98x 1.20 (R 2 ϭ 0.95).
For patient results obtained by the Owren (Nycotest PT) and Quick methods using 0.129 and 0.109 mol/L citrate samples, for results Ͻ2.0 INR, the differences between the methods were not clinically significant with both sample types (Table 1) . For results Ͼ2.0 INR, however, the means of the differences were clinically high and thus significant with both sample types. The Bland and Altman method (13 ) was not suitable for analyzing results in the range Ͼ2 INR before correction because the distribution was not gaussian (Table 1 and Fig. 1A) Altman (13 ), 8 results of 157 could be beyond the limits (Fig. 1B) . With a probability of 94%, the clinical significance of the results is the same.
The mean Ca 2ϩ concentrations in the reaction mixtures for the Owren and Quick methods using both citrate samples (0.129 or 0.109 mol/L) are given in Table 1 .
In the comparison of one Owren and the Quick method, we obtained fairly good nonlinear correlation using both citrate samples (R 2 ϭ 0.95 for 0.129 mol/L; R 2 ϭ 0.97 for 0.109 mol/L). The correlation equations were the power functions (y ϭ 0.98x 1.20 and y ϭ 1.007x 1.14 , and the differences were clinically significant for both citrate concentrations ( Table 1 ). The patients whose samples were analyzed by Owren PT methods received too much medication, and this should be reduced. Oral anticoagulant therapy recommendations are based on Quick PT (5, 11 ) . In published scientific reports, the situation was the same in that the results were not equal. Using ISI correction (Owren ISI ϫ 1.20 for 0.129 mol/L; Owren ISI ϫ 1.14 for 0.109 mol/L), we can unify the results clinically with a probability of 94%.
In a previous study (10 ) The two different Owren reagents show good correlation (R 2 ϭ 0.99), and the results involve no clinically significant difference.
The physiological concentration of Ca 2ϩ in plasma is When a sample is diluted (1 ϩ 9) with citrate solution, the dilution occurs in plasma, not in whole blood, and depending on the hematocrit, the plasma volume will differ from sample to sample. The situation is similar if too little blood is drawn into the collection tube and the tube is underfilled. The Ca 2ϩ concentration in patient plasma can sometimes be low. The citrate concentration is markedly variable in plasma, as well as in the coagulation reaction mixture in the Quick method.
Because the Ca 2ϩ concentration is lower in 0.129 mol/L citrate samples, the times for PT coagulation and activated partial thromboplastin time measurements are longer than the corresponding times for patient samples containing 0.109 mol/L citrate for patient groups designated as "no anticoagulant therapy" and "anticoagulant therapy" when PT (ISI, 1.0; Quick method) and activated partial thromboplastin time reagents are used (9 ). Duncan et al. (8 ) showed that the concentration of citrate in the sample affects the results and ISI calibration (Quick methods). The citrate concentration exerts an ϳ10% effect on the ISI of reagents. The above-mentioned results of two studies agree well with the PT and calcium results in our study.
With Owren's PT, the mean difference in the Ca 2ϩ concentration in the reaction mixture was 0.01 mmol/L (0.4%) and the CVs were 4.9% for 0.129 mol/L citrate and 3.0% for 0.109 mol/L. The sample citrate concentration has no effect on the Owren method, and this method is also less sensitive to other preanalytical variables by reason of the small sample volume (5%) in the reaction mixture. Because the Owren and Quick methods depend differently on sample citrate concentrations (Ca 2ϩ in the reaction mixture), the correlation is not so good.
We subscribe to the demand for unification of recommendations of a sample citrate concentration of 0.109 mol/L to improve results for PT and activated partial thromboplastin times (8, 9 ) . For results obtained by the Owren method, ISI correction should be used to standardize patient INR results and anticoagulant therapy to be the same as the results obtained by the Quick method because the recommendations for care are made according to the Quick method. The patients whose samples were analyzed by the Owren method were receiving too much medication and were in greater danger of bleeding.
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